asa 81mg
TRANSCRIPT
NURS 2516 Clinical Medications Worksheets(You will need to make additional copies of these forms)
Generic NameASA
Trade NameBayer Aspirin
ClassificationSalicylates
Dose81 mgDosage range:1 baby asparin daily for decreased platelet aggregation
Routepo
Time/frequency0900 qd
Peak1-3 hr
Onset5-30 min
Duration3-6 hr
For IV meds, compatibility with IV drips and /or solutionsN/A
Mechanism of action and indications(Why med ordered)Decreases platelet aggregation, indicated for prevention of DVT/PE
Nursing Implications (what to focus on) Contraindications/warnings/interactionsHypersensitivity to aspirin, tartrazine (FDC yellow dye #5), or other salicylatesCross-sensitivity with other NSAIDs may exist (less with nonaspirin salicylates)Bleeding disorders or thrombocytopenia (more important with aspirin)Common side effectsdyspepsia, epigastric distress, heartburn, nausea
Interactions with other patient drugs, OTC or herbal medicines (ask patient specifically)
Lanoxin (may increase the risk for bleeding)
Lab value alterations caused by medicineMay cause ↑ serum AST, ALT, and alkaline phosphatase, especially when plasma concentrations exceed 25 mg/100 ml. May alter results of serum uric acid, urine vanillylmandelic acid (VMA), protirelin-induced thyroid-stimulating hormone (TSH), urine hydroxyindoleacetic acid (5-HIAA) determinations, and radionuclide thyroid imaging. May cause ↓ serum potassium and cholesterol concentrations.Be sure to teach the patient the following about this medicationAdvise patients receiving aspirin prophylactically to take only prescribed dose. Increasing the dose has not been found to provide additional benefits. Instruct patient to take salicylates with a full glass of water and to remain in an upright position for 15-30 min after administration.
Nursing Process- Assessment(Pre-administration assessment)Patients who have asthma, allergies, and nasal polyps or who are allergic to tartrazine are at an increased risk for developing hypersensitivity reactions
AssessmentWhy would you hold or not give this med?onset of tinnitus, headache, hyperventilation, agitation, mental confusion, lethargy, diarrhea, and sweating.
EvaluationCheck after givingPrevention of DVT/PE